Friday, May 29, 2020

Hua Medicine Breaking New Ground

This month's Innovation That Matters features an interview Dr. Li Chen, CEO of Hua Medicine.  Chen and his colleagues at Hua had much to celebrate in November as their novel Type II...

Expediting Development of Biologics in China: From Strategy to Regulatory Expectations and Beyond

Addressing "availability and affordability" of novel biologics will be the focus of China's life science industry in the foreseeable future. Few biologic drugs are currently available in China, despite the increasing...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WuXi NEWS